Prnewswire·2025-11-06 13:00Core Insights - Atossa Therapeutics is advancing its research on (Z)-endoxifen for breast cancer treatment and prevention, with four abstracts accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS) [1][2]. Presentation Details - The first poster presentation will cover initial results from the RECAST DCIS trial, focusing on active surveillance and novel endocrine therapy agents for DCIS management, scheduled for December 11, 2025 [3]. - The second presentation will discuss the use of low-dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot, also on December 11, 2025 [3]. - The third presentation will explore how (Z)-endoxifen maintains ER antagonist function against ESR1 mutants, scheduled for December 12, 2025 [3]. - The final presentation will detail a randomized Phase 2 non-inferiority trial comparing (Z)-endoxifen plus Goserelin versus Exemestane plus Goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer, set for December 12, 2025 [3]. Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet needs in breast cancer, emphasizing disciplined capital allocation to support future regulatory submissions and potential commercialization [4].